Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells

Summary: Emerging evidence indicates that the Achilles' heel of cancer immunotherapies is often the complex interplay of tumor‐derived factors and deviant host properties, which involve a wide range of immune elements in the lymphoid and myeloid compartments. Regulatory lymphocytes, tumor‐conditioned myeloid‐derived suppressor cells (MDSCs), tumor‐associated macrophages, and dysfunctional and immature dendritic cells take part in a complex immunoregulatory network. Despite the fact that some mechanisms governing tumor‐induced immune tolerance and suppression are starting to be better understood and their complexity dissected, little is known about the diachronic picture of immune tolerance. Based on observations of MDSCs, we present a time‐structured and topologically consistent idea of tumor‐dependent tolerance progression in tumor‐bearing hosts.

[1]  G. Galbraith.  A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2008 .

[2]  C. Divino,et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. , 2008, Blood.

[3]  J. Berzofsky,et al.  Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis1 , 2007, The Journal of Immunology.

[4]  B. Pulendran,et al.  Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17–producing T cell responses , 2007, Nature Immunology.

[5]  D. Massi,et al.  Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: evidence from human and experimental tumors. , 2007, Human pathology.

[6]  P. Tripathi.  Nitric oxide and immune response. , 2007, Indian journal of biochemistry & biophysics.

[7]  F. Liew,et al.  Nitric oxide induces CD4+CD25+ Foxp3− regulatory T cells from CD4+CD25− T cells via p53, IL-2, and OX40 , 2007, Proceedings of the National Academy of Sciences.

[8]  J. Sosman,et al.  Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses , 2007, Clinical Cancer Research.

[9]  A. Viola,et al.  Metabolic mechanisms of cancer-induced inhibition of immune responses. , 2007, Seminars in cancer biology.

[10]  Csaba Szabó,et al.  Peroxynitrite: biochemistry, pathophysiology and development of therapeutics , 2007, Nature Reviews Drug Discovery.

[11]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[12]  S. Ko,et al.  A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. , 2007, Cancer research.

[13]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[14]  S. R. Himes,et al.  Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony‐stimulating factor receptor (CSF‐1R) as well as many other macrophage‐specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF‐1 , 2007, Journal of leukocyte biology.

[15]  Peter Möller,et al.  Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. , 2007, Blood.

[16]  L. Mariani,et al.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Fujiwara,et al.  Myeloid suppressor cell‐associated immune dysfunction in CSA1M fibrosarcoma tumor‐bearing mice , 2007, Cancer science.

[18]  C. Aspord,et al.  Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development , 2007, The Journal of experimental medicine.

[19]  R. Kastelein,et al.  Swords into plowshares: IL-23 repurposes tumor immune surveillance. , 2007, Trends in immunology.

[20]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[21]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[22]  J. Kappes,et al.  Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. , 2007, Blood.

[23]  G. Parmiani,et al.  Tumor-released microvesicles as vehicles of immunosuppression. , 2007, Cancer research.

[24]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[25]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[26]  A. Malkinson,et al.  Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. , 2007, The American journal of pathology.

[27]  B. Tóth,et al.  Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. , 2007, International immunopharmacology.

[28]  P. Rodriguez,et al.  Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[29]  M. Colombo,et al.  Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Divino,et al.  Reversion of immune tolerance in advanced malignancy : modulation of myeloid derived suppressor cell development by blockade of SCF function , 2007 .

[31]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[32]  J. Califano,et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.

[33]  Paolo Serafini,et al.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.

[34]  O. Levy,et al.  TCR ζ Down-Regulation under Chronic Inflammation Is Mediated by Myeloid Suppressor Cells Differentially Distributed between Various Lymphatic Organs1 , 2006, The Journal of Immunology.

[35]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[36]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[37]  A. Villa,et al.  Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. , 2006, Cancer research.

[38]  K. Mills,et al.  Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells1 , 2006, The Journal of Immunology.

[39]  Yuan Zhang,et al.  CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. , 2006, Cancer research.

[40]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[41]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[42]  D. Munn.  Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. , 2006, Current opinion in immunology.

[43]  Richard A Flavell,et al.  Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.

[44]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[45]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[46]  J. Leips,et al.  Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1 , 2006, The Journal of Immunology.

[47]  S. Cingarlini,et al.  Leukocyte Infiltration in Cancer Creates an Unfavorable Environment for Antitumor Immune Responses: A Novel Target for Therapeutic Intervention , 2006, Immunological investigations.

[48]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[49]  P. Sinha,et al.  Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. , 2005, Cancer research.

[50]  M. Lutz,et al.  Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro , 2005, European journal of immunology.

[51]  D. Gabrilovich,et al.  Tumor Associated CD8+ T-Cell Tolerance Induced by Bone Marrow Derived Immature Myeloid Cells , 2005 .

[52]  S. Dubinett,et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.

[53]  D. Gabrilovich,et al.  Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1 , 2005, The Journal of Immunology.

[54]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[55]  T. Coelho-Sampaio,et al.  Heparin-binding Sites in Granulocyte-Macrophage Colony-stimulating Factor , 2005, Journal of Biological Chemistry.

[56]  I. Bechmann,et al.  Indolamine 2,3‐dioxygenase is expressed in the CNS and down‐regulates autoimmune inflammation , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[58]  P. Sinha,et al.  Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression , 2005, Cancer Immunology, Immunotherapy.

[59]  F. Montorsi,et al.  Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction , 2005, Nature Clinical Practice Urology.

[60]  A. Viola,et al.  Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers , 2005, The Journal of experimental medicine.

[61]  D. Gabrilovich,et al.  STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion1 , 2005, The Journal of Immunology.

[62]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[63]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[64]  L. Roman,et al.  L-arginine regulates neuronal nitric oxide synthase production of superoxide and hydrogen peroxide. , 2005, Biochemical pharmacology.

[65]  P. Musiani,et al.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Drake,et al.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. , 2005, Cancer cell.

[67]  P. Sinha,et al.  Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.

[68]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[69]  Simone Mocellin,et al.  Part I: Vaccines for solid tumours. , 2004, The Lancet. Oncology.

[70]  N. Fusenig,et al.  Cooperative Autocrine and Paracrine Functions of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in the Progression of Skin Carcinoma Cells , 2004, Cancer Research.

[71]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[72]  T. Ley,et al.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death. , 2004, Immunity.

[73]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[74]  T. Hirano,et al.  IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation1 , 2004, The Journal of Immunology.

[75]  V. Bronte,et al.  High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells , 2004, Cancer Research.

[76]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[77]  A. Rudensky,et al.  Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. , 2004, Immunity.

[78]  D. Herndon,et al.  Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. , 2004, Immunity.

[79]  E. Raz,et al.  Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. , 2004, The Journal of clinical investigation.

[80]  B. Baban,et al.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.

[81]  J. Pollard,et al.  Role of infiltrated leucocytes in tumour growth and spread , 2004, British Journal of Cancer.

[82]  D. Gabrilovich,et al.  Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1 , 2004, The Journal of Immunology.

[83]  Andrew V. Nguyen,et al.  The Macrophage Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression , 2002, Journal of Mammary Gland Biology and Neoplasia.

[84]  E. Shevach,et al.  Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.

[85]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[86]  Joseph I. Clark,et al.  Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3 , 2004, Cancer Immunology, Immunotherapy.

[87]  J. Berzofsky,et al.  Role of IL-13 in regulation of anti-tumor immunity and tumor growth , 2004, Cancer Immunology, Immunotherapy.

[88]  S. Cingarlini,et al.  Derangement of immune responses by myeloid suppressor cells , 2004, Cancer Immunology, Immunotherapy.

[89]  I. Buschmann,et al.  Divergent effects of GM‐CSF and TGFβ1 on bone marrow‐ derived macrophage arginase‐1 activity, MCP‐1 expression, and matrix‐metalloproteinase‐12: a potential role during arteriogenesis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  U. Grohmann,et al.  Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.

[91]  J. Rossi,et al.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  G. Gasparini,et al.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? , 2003, The Lancet. Oncology.

[93]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[94]  D. Gabrilovich,et al.  Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species , 2003, Journal of leukocyte biology.

[95]  J. Ochoa,et al.  l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes1 , 2003, The Journal of Immunology.

[96]  Bin Yu,et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.

[97]  G. Dranoff.  GM-CSF-secreting melanoma vaccines , 2003, Oncogene.

[98]  U. Grohmann,et al.  Tolerance, DCs and tryptophan: much ado about IDO. , 2003, Trends in immunology.

[99]  A. Morelli,et al.  Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. , 2003, Gastroenterology.

[100]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[101]  M. Colombo,et al.  IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.

[102]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[103]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[104]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[105]  M. Makuuchi,et al.  G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. , 2002, Biochemical and biophysical research communications.

[106]  A. Sharpe,et al.  CD80+Gr-1+ Myeloid Cells Inhibit Development of Antifungal Th1 Immunity in Mice with Candidiasis1 , 2002, The Journal of Immunology.

[107]  V. Praloran,et al.  Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis , 2002, Urological Research.

[108]  Kevin Hsueh,et al.  Characterization of the human homolog of the IL-4 induced gene-1 (Fig1). , 2002, Biochimica et biophysica acta.

[109]  K. Koshimura,et al.  Effect of Continuous Subcutaneous Administration of a Low Dose of G-CSF on Stem Cell Mobilization in Healthy Donors: A Feasibility Study , 2002, International journal of hematology.

[110]  D. Gabrilovich,et al.  Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.

[111]  L. Que,et al.  Effects of arginase isoforms on NO Production by nNOS. , 2002, Nitric oxide : biology and chemistry.

[112]  P. H. Correll,et al.  Activation of the Stem Cell-Derived Tyrosine Kinase/RON Receptor Tyrosine Kinase by Macrophage-Stimulating Protein Results in the Induction of Arginase Activity in Murine Peritoneal Macrophages1 , 2002, The Journal of Immunology.

[113]  A. Visintin,et al.  Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.

[114]  V. Bronte,et al.  Tumor-induced immune dysfunctions caused by myeloid suppressor cells. , 2001, Journal of immunotherapy.

[115]  C. Gerharz,et al.  Secretion of GM-CSF and M-CSF by human renal cell carcinomas of different histologic types. , 2001, Urology.

[116]  B. Milleron,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma. , 2001, The American journal of pathology.

[117]  J. Garlick,et al.  Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. , 2001, The American journal of pathology.

[118]  C. Natanson,et al.  Safeguarding patients in clinical trials with high mortality rates. , 2001, American journal of respiratory and critical care medicine.

[119]  D. Geller,et al.  Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[120]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[121]  O. Finn,et al.  Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[122]  U. Walter,et al.  Activation of cGMP-dependent Protein Kinase Iβ Inhibits Interleukin 2 Release and Proliferation of T Cell Receptor-stimulated Human Peripheral T Cells* , 2001, The Journal of Biological Chemistry.

[123]  J. Ihle,et al.  Cutting Edge: Stat6-Dependent Substrate Depletion Regulates Nitric Oxide Production1 , 2001, The Journal of Immunology.

[124]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[125]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[126]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[127]  D. Speiser,et al.  Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.

[128]  T. Yoshikawa,et al.  Possible paracrine growth of adenocarcinoma of the stomach induced by granulocyte colony stimulating factor produced by squamous cell carcinoma of the oesophagus , 2000, Gut.

[129]  K. Zier,et al.  Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity1 , 2000, The Journal of Immunology.

[130]  D. Elder,et al.  TIA-1 Positive Tumor-Infiltrating Lymphocytes in Nevi and Melanomas , 2000, Modern Pathology.

[131]  R. Ronca,et al.  Identification of a CD 11 b 1 / Gr-1 1 / CD 31 1 myeloid progenitor capable of activating or suppressing CD 8 1 T cells , 2000 .

[132]  K Eichmann,et al.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. , 1999, Journal of immunology.

[133]  B. Mayer,et al.  Enzymatic function of nitric oxide synthases. , 1999, Cardiovascular research.

[134]  A. Chompret,et al.  Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72) , 1999, International journal of cancer.

[135]  P. Hwu,et al.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. , 1999, Journal of immunology.

[136]  J. Blay,et al.  Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. , 1998, Blood.

[137]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[138]  D. Geller,et al.  Cytokine induction of NO synthase II in human DLD‐1 cells: roles of the JAK‐STAT, AP‐1 and NF‐κB‐signaling pathways , 1998, British journal of pharmacology.

[139]  J. Zweier,et al.  Inducible Nitric-oxide Synthase Generates Superoxide from the Reductase Domain* , 1998, The Journal of Biological Chemistry.

[140]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[141]  P. Holt,et al.  Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. , 1998, Journal of immunology.

[142]  M. Asaka,et al.  Monoclonal origin of an esophageal carcinosarcoma producing granulocyte‐colony stimulating factor , 1998, Cancer.

[143]  W. Farrar,et al.  Nitric oxide and thiol redox regulation of Janus kinase activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[144]  R. Kirken,et al.  Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. , 1997, Journal of immunology.

[145]  J. Zweier,et al.  Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[146]  T. Lapidot,et al.  Increased circulating colony-stimulating factor-1 (CSF-1) in SJL/J mice with radiation-induced acute myeloid leukemia (AML) is associated with autocrine regulation of AML cells by CSF-1. , 1997, Blood.

[147]  J. Leonetti,et al.  Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte‐macrophage colony‐stimulating factor and contained CD34+ natural suppressor cells , 1997, International journal of cancer.

[148]  T. Saito,et al.  Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[149]  M. Young,et al.  Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. , 1996, Cancer letters.

[150]  J. Moulinoux,et al.  Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. , 1995, Journal of immunology.

[151]  A. S. Pak,et al.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[152]  A. S. Pak,et al.  1α,25-Dihydroxyvitamin D3 plus γ-Interferon Blocks Lung Tumor Production of Granulocyte-Macrophage Colony-stimulating Factor and Induction of Immunosuppressor Cells , 1993 .

[153]  A. S. Pak,et al.  1 alpha,25-dihydroxyvitamin D3 plus gamma-interferon blocks lung tumor production of granulocyte-macrophage colony-stimulating factor and induction of immunosuppressor cells. , 1993, Cancer research.

[154]  M. Tsukuda,et al.  Production of granulocyte colony-stimulating factor by head and neck carcinomas , 1993, Biotherapy.

[155]  M. Young,et al.  Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. , 1993, Invasion & metastasis.

[156]  J. Cunningham,et al.  Transport of cationic amino acids by the mouse ecotropic retrovirus receptor , 1991, Nature.

[157]  E. Vellenga,et al.  Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. , 1988, The Journal of clinical investigation.

[158]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[159]  G. Mann,et al.  Regulation of Amino Acid Influx and Efflux at the Basolateral Plasma Membrane of the Salivary Gland Epithelium: Effects of Parasympathetic Nerve Stimulation , 1987, Journal of dental research.

[160]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[161]  A. Waheed,et al.  Peritoneal macrophages exposed to purified macrophage colony-stimulating factor (M-CSF) suppress mitogen- and antigen-stimulated lymphocyte proliferation. , 1986, Journal of immunology.